UK markets closed

Nanobiotix S.A. (NNBXF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
9.100.00 (0.00%)
As of 02:47PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close9.10
Open9.10
BidN/A x N/A
AskN/A x N/A
Day's range9.10 - 9.10
52-week range7.32 - 19.85
Volume100
Avg. volume64
Market capN/A
Beta (5Y monthly)1.86
PE ratio (TTM)N/A
EPS (TTM)-1.42
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    NANOBIOTIX to Present at the 5th Annual Evercore ISI HealthCONx Conference

    PARIS and CAMBRIDGE, Mass., Nov. 15, 2022 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that Laurent Levy, co-founder and chairman of the executive board, and Bart Van Rhijn, chief financial officer, will participate in a virtual fireside chat at the 5th annual Evercore ISI HealthCONx Conference on Thursda

  • Globe Newswire

    NANOBIOTIX Announces Recommended Phase 2 Dose for NBTXR3 in Pancreatic Cancer

    Data show that radiotherapy-activated NBTXR3 was feasible and well tolerated in the complete dose escalation part of a Study 2019-1001, a phase 1 evaluation of NBTXR3 for patients with locally advanced pancreatic adenocarcinomaThe recommended phase 2 dose for radiotherapy-activated NBTXR3 in pancreatic cancer was established at 42% of gross tumor volume and the dose expansion part of the study is ongoing in the United StatesThe company expects to report safety and early efficacy data from the es

  • Globe Newswire

    NANOBIOTIX Reports Updated Phase 1 Anti-PD-1 Combination Data That May Support the Immune Stimulation Potential of Radioenhancer NBTXR3 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer

    Data to be discussed during Nanobiotix Q3 Earnings Call at 8:00AM ESTData show that radiotherapy-activated NBTXR3 followed by anti-PD-1 was feasible and well tolerated in the complete dose escalation part of the Company’s phase 1 immunotherapy study with a recommended phase 2 dose established at 33% of gross tumor volume in all 3 cohortsResults include 5 additional patients of 21 evaluable as of the data cutoff on 22 August 2022 and continue to suggest local control and immune stimulation regard